Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | PRKCB | P05771 | 14/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 1.00 |
| ▸ | PRKCG | P05129 | 6/20 | 0.62 |
| ▸ | PRKCA | P17252 | 6/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349483 | 0.81 | GSK3B (0.68) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL2982584 | 0.80 | GSK3B (1.00) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL13204279 | 0.80 | GSK3B (0.67) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL13204307 | 0.79 | GSK3B (0.69) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL2983553 | 0.78 | GSK3B (1.00) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL13437553 | 0.78 | GSK3B (0.64) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL13204135 | 0.77 | GSK3B (0.72) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL13204137 | 0.77 | GSK3B (0.72) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL2985656 | 0.77 | GSK3B (1.00) | GSK3BPRKCBCCNA2CDK2CCNB2 | |
| SCHEMBL14257784 | 0.77 | GSK3B (0.70) | GSK3BPRKCBCCNA2CDK2CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885PRKCB 61/4885CCNA2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.